Biopharma takeovers show quantity, if not quality
Second-quarter deal values plummeted as Covid-19 spread and the prices of target companies spiralled.
Menarini Silicon Biosystems banks on cells for its liquid biopsy
The group has the only approved cell-based cancer blood test in the world, but competing in an increasingly cutthroat market will be tough.
Astra and Daiichi lay out their plan for a better Herceptin
The companies’ DS-8201 succeeds in breast cancer patients who had failed Kadcyla, and will go before the regulators later this year.
Seeking alpha in PI3K inhibition
Novartis hails the most advanced alpha-directed PI3K inhibitor after success in breast cancer, but it’s not the only one.
Aveo comeback highlights a transatlantic split
Most drugs get the nod in the US before Europe – but there are some cases where the usual trend is reversed.
Aveo comeback highlights a transatlantic split
After the recent EU positive opinion for Aveo's tivozanib, EP Vantage takes a look at other projects approved in the EU, but not the US.
